# US 2016/0354435 A1 · Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354435 A1
- Document ID: US20160354435A1
- Status: Published application
- Kind: A1
- Application number: 14/733,876
- Filed: 2015-06-08
- Published: 2016-12-08
- Earliest claimed: 2015-06-08
- Assignees: Retinal Solutions LLC
- Inventors: Michael T. Trese; Antonio Capone, JR.; Kimberly Drenser
- Web page: https://patentgrep.com/patent/US20160354435A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/515: Angiogenesic factors; Angiogenin
- C07K 16/22: against growth factors {; against growth regulators}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method of tightening inter-cellular junctions in endothelial or epithelial cells includes exposing the endothelial or epithelial cells cells to norrin. Upon sufficient contact time, for norrin to selectively up- regulate gene expression of Cadherin or claudin-5 in the endothelial or epithelial cells, the inter-cellular junctions are tightened.

## Claims

### Claim 1

A method of tightening inter-cellular junctions in endothelial or epithelial cells defining a tissue comprising:
administering an effective amount of norrin to the endothelial or epithelial cells; and
allowing sufficient time for said norrin to selectively up-regulate gene expression of Cadherin and claudin-5 in the endothelial or epithelial cells to tighten the inter-cellular junctions of the tissue for prevention of vascular leakage or repair of the vascular leakage.

### Claim 2 (depends on 1)

The method of claim 1, wherein the endothelial or epithelial cells are in vivo in a subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein the endothelial or epithelial cells are endothelial cells that define a vascular membrane.

### Claim 4 (depends on 2)

The method of claim 2, wherein the endothelial or epithelial cells are endothelial cells that define a lymphatic capillary.

### Claim 5 (depends on 2)

The method of claim 2, wherein the endothelial or epithelial cells are endothelial cells that define a blood-brain barrier membrane.

### Claim 6 (depends on 2)

The method of claim 2, wherein the endothelial or epithelial cells are epithelial cells that define a blood-intestinal membrane.

### Claim 7 (depends on 2)

The method of claim 2, wherein the administering step is by systemic injection.

### Claim 8 (depends on 2)

The method of claim 2, wherein the administering step is by topical administration to epithelial cells.

### Claim 9 (depends on 2)

The method of claim 2, wherein said subject is human.

### Claim 10 (depends on 2)

The method of claim 2, wherein said subject is one of: cow, horse, sheep, pig, goat, chicken, cat, dog, mouse, guinea pig, hamster, rabbit, rat, or a cell from one of the aforementioned.

### Claim 11 (depends on 1)

The method of claim 1, further comprising diagnosing edema associated with fluid leakage from a compromised cellular junction in the endothelial or epithelial cells prior to the administering step.

### Claim 12 (depends on 1)

The method of claim 1, wherein said norrin is a polypeptide of SEQ NO. 2.

### Claim 13 (depends on 1)

The method of claim 1, wherein said norrin is a fragment of SEQ ID. NO. 1 that binds a frizzled-4 receptor of the endothelial or epithelial cells.

### Claim 14 (depends on 1)

The method of claim 1, wherein said norrin is recombinant.

### Claim 15 (depends on 1)

The method of claim 1 wherein the tissue is experiencing edema prior to the administering step.

### Claim 16 (depends on 13)

The method of claim 13, wherein the endothelial or epithelial cells are endothelial cells and are retinal vessel cells.
